International Journal of Rheumatology / 2010 / Article / Tab 1

Review Article

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

Table 1

Serial functional, hemodynamic, and laboratory parameters before and after the tocilizumab treatment.

Pretreatment3 months6 months9 months12 months

NYHA functional classIIIIIIII
6MWD (m)310434NDND663
Mean PAP (mmHg)4331NDND27
PCWP (mmHg)114NDND4
RAP (mmHg)122NDND3
Systemic venous oxygen saturation (%)52.169.4NDND75.3
Cardiac output (L/min)5.54.5NDND4.4
PVR (wood unit)5.85.6NDND5.3
Doppler systolic PAP (mmHg)10090725154
BNP (pg/mL)18148444637
CRP (mg/dL)9.010.540.250.120.04
IgG (mg/dL)6,4513,2662,6792,4332,238
Hemoglobin (g/dL)8.012.913.913.012.8
IL-6 (pg/mL)41.81,100801806756

ND, 6MWD and hemodynamic assessment by right heart catheterization were not done at 6 and 9 months.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.